This week we come to meta-analyse, strikingly late, the cornerstone of all CKD treatments. Are you still in doubt? We need ACEing CKD to the end of GFR, and beyond
This week, we will discuss hopefully the final story of intensive BP lowering. BPROAD is a larger version of ACCORD without the glycemic control arm. Dive in.
This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.
This week, we will discuss post-trial follow-up for EMPA-Kidney. What are the longer-term effects of empagliflozin for patients with chronic kidney disease?
This week on #NephTrials, we will discuss platform trials, anchoring the discussion to the BEAT-Calci trial, which has a number of interesting design features.
In this edition of NephTrials, we will discuss the bewildering world of master protocols, comprising of platform, umbrella and basket trials - with the example of the RENAL LIFECYCLE trial.
After cluster RCTs and pragmatic trials, we will discuss the role of run in periods and what we try to achieve by having them in clinical trials. Read on.
This week we discuss cluster RCTs. How do you conduct, consent, analyse and interpret these? Why do you do cluster RCTs? Let’s discuss using the Dial-Mag trial as an example.
Join us for the first edition of the #NephTrials chat. Let’s take a deep dive into pragmatic trials, and take a specific example - the Phosphate trial, to anchor the discussion.
NephTrials: where NephJC joins forces with ISN ACT and ISN Academy, to bring the social media expertise from the NephJC community and the methods expertise from ISN-ACT.